A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

June 11, 2013

Primary Completion Date

July 17, 2019

Study Completion Date

July 17, 2019

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.

Trial Locations (61)

2100

CH de Saint Quentin, Saint-Quentin

13273

Institut Paoli Calmettes; Oncologie Medicale, Marseille

14076

Centre Francois Baclesse; Oncologie, Caen

21079

Centre Georges Francois Leclerc; Oncologie 3, Dijon

25030

HOPITAL JEAN MINJOZ; Oncologie, Besançon

28630

Ch Louis Pasteur; Oncologie, Le Coudray

29107

Chi De Cornouaille; Oncologie Hospitalisation, Quimper

29200

Hopital Morvan, Brest

29220

Clinique Pasteur Lanroze; Chimiotherapie Radiotherapie, Brest

30029

Institut de cancerologie du Gard, Nîmes

31059

Hôpital Rangueil - CHU de Toulouse, Toulouse

31076

Clinique Pasteur; Oncologie Medicale, Toulouse

33076

Institut Bergonie, Bordeaux

34070

Clinique Clementville; Hopital De Jour, Montpellier

35042

Centre Eugene Marquis; Bureau D Etudes Cliniques, Rennes

35768

Chp Saint Gregoire; Cancerologie Radiotherapie, Saint-Grégoire

42271

Institut de Cancérologie de Loire, Saint-Priest-en-Jarez

44202

Centre Catherine de Sienne; Chimiotherapie, Nantes

44606

Clinique Mutualiste L Estuaire, Saint-Nazaire

44805

Centre Rene Gauducheau, Saint-Herblain

45100

HOPITAL DE LA SOURCE; Service de Cardiologie, Point Jaune, Orléans

47000

Clinique Du Docteur Calabet; Cromg, Agen

49055

ICO Paul Papin; Oncologie Medicale., Angers

51056

Institut Jean Godinot; Oncologie Medicale, Reims

51100

Institut du Cancer Coulancy Reims, Reims

54100

Polyclinique Gentilly; CHIMIOTHERAPIE AMBULATOIRE, Nancy

56100

Ch Bretagne Sud Site Scorff; Oncologie Medicale, Lorient

57045

Hopital Belle Isle; Oncologie Hematologie, Metz

57085

Hopital de Mercy ;ONCOLOGIE MEDICALE, Melz-sur-Seine

59003

Polyclinique Du Bois; Oncologie, Lille

59020

Centre Oscar Lambret; Unite de Recherche Clinique, Lille

59187

Centre Leonard De Vinci;Chimiotherapie, Dechy

62012

HOP Prive Arras Les Bonnettes; Chimiotherapie, Arras

62280

CMCO De La Cote D Opale; Auberge De Jour, Saint-Martin-Boulogne

63011

Centre Jean Perrin; Oncologie, Clermont-Ferrand

63050

Pole Sante Republique;Oncologie Hematologie, Clermont-Ferrand

64109

Centre Hospitalier de La Cote Basque; Oncologie, Bayonne

64501

Polyclinique de la Cote Basque Sud; Oncologie, Saint-Jean-de-Luz

67000

Clinique Ste Anne, Strasbourg

67065

Centre Paul Strauss; Oncologie Medicale, Strasbourg

67091

Hopital de Hautepierre, Strasbourg

69008

Centre Leon Berard, Lyon

69337

Clinique De La Sauvegarde; Chimiotherapie, Lyon

69373

Hopital Prive Jean Mermoz, Lyon

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

72015

Clinique Victor Hugo; Radiotherapie, Le Mans

74370

CH d'Annecy, Pringy

75013

APHP - Hopital de la Pitie Salpetriere, Paris

75020

Groupe Hospitalier Diaconesses, Paris

75231

Institut Curie; Oncologie Medicale, Paris

75475

Hopital Saint Louis; Oncologie Medicale, Paris

75970

HOPITAL TENON; Cancerologie Medicale, Paris

76038

Centre Henri Becquerel; Oncologie Medicale, Rouen

80090

Clinique De L Europe; Radiotherapie Chimiotherapie, Amiens

84082

Institut Sainte-Catherine; Oncologie, Avignon

85925

CHD Les Oudairies, La Roche-sur-Yon

86021

Centre Hospitalier Universitaire de Poitiers, Poitiers

94010

Chi De Creteil; Radiotherapie Oncologie, Créteil

95200

Hopital Prive Nord Parisien; Soins De Suite - Oncologie, Sarcelles

01012

Centre Hospitalier Fleyriat; Oncologie/Hematologie, Bourg-en-Bresse

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01810393 - A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years | Biotech Hunter | Biotech Hunter